Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Outcome of Nodular Lymphocyte Predominant Hodgkin Lymphoma: A Finnish Nationwide Population-Based Study

Ilja Kalashnikov, MD, Nea Malila, MD PhD, Sirkku Jyrkkio, MD PhD, Sirpa Leppa, MD PhD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-139913

Published: 2020

Journal Articles

Clinical Impact of Tumor-Associated Macrophage and T-Cell Contents in Diffuse Large B-Cell Lymphoma

Matias Autio, MD, Suvi-Katri Leivonen, PhD, Teijo Pellinen, PhD, Sirpa Leppa, MD PhD

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-142331

Published: 2020

Journal Articles

Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma

Xiang Li, Rachel Kositsky, Anupama Reddy, PhD, Cassandra Love, Kikkeri Naresh, Jean L. Koff, MD, Ilja Nystrand, Sirpa Leppä, MD PhD, Annika Pasanen, MD PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Johannes Dunkel, Panu Kovanen, MD PhD, Qiu Qin, Govind Bhagat, MD, Rebecca J Leeman-Neill, MDPhD, Rashmi S. Goswami, MD PhD, Sarah Wildeman, Jan Delabie, MDPhD, Richard Burack, MD PhD, Andrew G Evans, MD PhD, Catalina Amador, MD, Ji Yuan, Hina Naushad Qureishi, Shaoying Li, MD, Jie Xu, C. Cameron Yin, MD PhD, Anne Ortved Gang, Peter H. Norgaard, MDPhD, Mette Ø Pedersen, MD, Jason Yongsheng Chan, MBBS, MRCP, Daryl Ming Zhe Cheah, Shin Yeu Ong, MD FRCPath, Chee Leong Cheng, FRCPA, FRCPath, MBBS, Lianne Lee, Felik Paulua, Sarah L. Ondrejka, DO, Eric D. Hsi, MD, Magdalena Czader, MD PhD, Lin Wang, PhD, Amber Landis, Michael C. Churnetski, David L. Jaye, MD, Christopher R. Flowers, MD MS, Chad M. McCall, MD PhD, Jadee Neff, MD PhD, Matthew S. McKinney, MD, Yuri Fedoriw, Eric Powers, Nathan D Montgomery, MD, Agata M. Bogusz, MDPhD, Andrea Stafford Hintz, HSLT, Alexandra E. Kovach, MD, Nishitha Reddy, MD, Mary Ann Thompson Arildsen, MD PhD, Emily F Mason, MD PhD, Ridas Juskevicius, MD, William Choi, MBBS,MRCP, Rex Au-Yeung, Eric Tse, MBBS, PhD FRCP, FRCPath, Vincent Sarno, Amy Chadburn, MD, Rafael Lopez, MD, Jennifer R Chapman, MD, Amir Behdad, MD, Neta Goldschmidt, MD, John Goodlad, MD, Cathy Burton, Raju Pillai, MD, Abner Louissaint, Jr., MD PhD, Dina Sameh Soliman, MD MB, MMSc, Razvan Panea, Tushar Dave, Barbara Xiong, Eileen Smith, Sandeep Dave, MD

Blood (2019) 134 (Supplement_1): 19.

https://doi.org/10.1182/blood-2019-130255

Published: 2019

Journal Articles

Mutational Dynamics and Evolutionary Divergence in DLBCL: A Call for Relapse Sampling

Blood (2019) 134 (Supplement_1): 1497.

https://doi.org/10.1182/blood-2019-131072

Published: 2019

Journal Articles

Genomic Profiling of Circulating Tumor DNA Reveals Patterns of Response and Refractoriness in Aggressive B-Cell Lymphoma - a Nordic Lymphoma Group Correlative Study

Leo Meriranta, MD, Amjad Alkodsi, PhD, Annika Pasanen, MD PhD, Maija Lepistö, MSc, Yngvild Nuvin Blaker, MD PhD, Matias Autio, Judit Jørgensen, MD PhD, Mats Jerkeman, MD Professor, Harald Holte, MD PhD, Pekka Ellonen, BSc, Sirpa Leppa, MD Prof

Blood (2019) 134 (Supplement_1): 1481.

https://doi.org/10.1182/blood-2019-132168

Published: 2019

Journal Articles

The DLBCL90 Double-Hit Gene Expression Signature Is Not Associated with Inferior Survival in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma Treated with Dose-Intensive Immunochemotherapy

Kathrine T. Isaksen, MD, Klaus Beiske, MD PhD, Erlend B. Smeland, MD PhD, Judit Jørgensen, MD PhD, Marianne Brodtkorb, MD PhD, June Helen Myklebust, PhD, Mats Jerkeman, MD Professor, Leo Meriranta, MD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Sirpa Leppa, MD PhD, David W. Scott, MBChB, PhD, Harald Holte, MD PhD, Yngvild Nuvin Blaker, MD PhD

Blood (2019) 134 (Supplement_1): 1485.

https://doi.org/10.1182/blood-2019-121467

Published: 2019

Journal Articles

Molecular Background of Double Protein Expressor B-Cell Lymphomas

Leo Meriranta, MD, Amjad Alkodsi, PhD, Annika Pasanen, MD PhD, Jari Haukka, PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Sirpa Leppa, MD Prof

Blood (2019) 134 (Supplement_1): 2781.

https://doi.org/10.1182/blood-2019-131220

Published: 2019

Journal Articles

Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies

Pier Luigi Zinzani, MD, Armando Santoro, Luigina Mollica, MD FRCPC, PhD, Sirpa Leppä, MD PhD, George A Follows, MD PhD, Georg Lenz, MD, Won Seog Kim, MD PhD, Arnon Nagler, MD MSc, Panayiotis Panayiotidis, MD, Judit Demeter, MD PhD Dr. Sci, Franck Morschhauser, MD, Javier Munoz, MD MS, FACP, Ashok Miriyala, MD, Alice Benson, PhD, Jose Garcia-Vargas, MD, Barrett H Childs, MD, Martin Dreyling, MD

Blood (2019) 134 (Supplement_1): 4009.

https://doi.org/10.1182/blood-2019-131779

Published: 2019

Journal Articles

Molecular Profiling of Aggressive Non-Hodgkin Lymphoma - Results from a Phase 1/2 Preben Study

Suvi-Katri Leivonen, PhD, Judit Jørgensen, MD PhD, Thomas Stauffer Larsen, MD PhD, Annika Pasanen, MD PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Helle M Toldbod, PhD, Francesco d'Amore, MD PhD, Sirpa Leppa, MD PhD

Blood (2019) 134 (Supplement_1): 5314.

https://doi.org/10.1182/blood-2019-129113

Published: 2019

Journal Articles

Tumor Microenvironment Differs between Germinal Centre B-Cell and Non-Germinal Centre B-Cell like Diffuse Large B-Cell Lymphomas and Has Subtype-Specific Prognostic Impact on Survival

Matias Autio, Suvi-Katri Leivonen, PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Teijo Pellinen, PhD, Sirpa Leppa, MD PhD

Blood (2019) 134 (Supplement_1): 5230.

https://doi.org/10.1182/blood-2019-129681

Published: 2019

Journal Articles

Immunogenomic Landscape of Hematological Malignancies

Olli Dufva, Petri Pölönen, MSc, Oscar Brück, MD, Mikko A Keränen, MD PhD, Juha Mehtonen, MSc, Sanna M. Siitonen, MD PhD, Suvi-Katri Leivonen, PhD, Leo Meriranta, MS, Sirpa Leppa, MD Prof, Matti Nykter, Olli Lohi, MD PhD, Merja Heinäniemi, PhD, Satu Mustjoki, MD PhD

Blood (2018) 132 (Supplement 1): 2596.

https://doi.org/10.1182/blood-2018-99-118335

Published: 2018

Journal Articles

Outcomes for Patients with High-Risk Relapsed or Refractory Indolent B-Cell Lymphoma Treated with Copanlisib in the CHRONOS-1 Study

Armando Santoro, MD, Luigina Mollica, MD PhD, Sirpa Leppa, MD Prof, George A Follows, MD PhD, Georg Lenz, Won Seog Kim, MD PhD, Arnon Nagler, MD, Maria Dimou, MD PhD, Judit Demeter, MD PhD Dr. Sci, Massimo Magagnoli, MD, Liana Rodrigues, MD, Oliver Wirtz, MSc, Florian Hiemeyer, MSc, Li Liu, PhD, Karl Koechert, PhD, Jose Garcia-Vargas, MD, Barrett H Childs, MD, Pier Luigi Zinzani, MD, Martin H. Dreyling, MD PhD

Blood (2018) 132 (Supplement 1): 395.

https://doi.org/10.1182/blood-2018-99-116715

Published: 2018

Journal Articles

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Francesco d'Amore, MD, Sirpa Leppä, MD, Maria Gomes da Silva, MD PhD, Thomas Relander, Grete Fossum Lauritzsen, Peter De Nully Brown, Antonio Pezzutto, Jeanette K. Doorduijn, MD PhD, Eckhart Weidmann, Michel van Gelder, Achiel Van Hoof, Ilse Christiansen, Unn Merete Fagerli, MD PhD, Hans Hagberg, MD, P.J. Lugtenburg, Jan Walewski, Ka Lung Wu, Hilde Maria Demuynck, Rob Fijnheer, Jacob H. Christensen, Milada Jankovská, MD, Pär L. Josefsson, Hanneke Kluin-Nelemans, Jose Mario Mariz, MD, Mats A. Merup, Thomas Noesslinger, Eric Van Den Neste, Josée M Zijlstra, MD, Georg Hopfinger, MD, VIT Prochazka, MD, Esa Jantunen, MD PhD, Ludmila Boudova, Jose Cabecadas, Andreas Chott, Jan M.A. Delabie, MD PhD, Laurence de Leval, MD, Arjan Diepstra, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Peter Noergaard, Andreas Rosenwald, Grzegorz Rymkiewicz, Christer Sundström, Lorenz Truemper, MD, Gerald Wulf, MD, Lauren Chong, MSc, Alyssa Bouska, PhD, Lynette Smith, Christian Gisselbrecht, Marita Ziepert, PhD, Markus Loeffler, MD, Knut Liestol, Christian Steidl, MD, Randy D. Gascoyne, MD, David W. Scott, PhDMD,FRACP,FRCPA, Bettina Altmann, PhD, Javeed Iqbal, §, Wing C Chan, MD, Helle Toldbod, MS,PhD

Blood (2018) 132 (Supplement 1): 998.

https://doi.org/10.1182/blood-2018-99-110429

Published: 2018

Journal Articles

B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)

Boris Boell, MD, Alexander Fosså, MD PhD, Helen Goergen, Peter Kamper, Sirpa Leppa, MD Prof, Daniel Molin, Julia Meissner, MD, Ellen Ritter, MD, Jacob H. Christensen, Martin Hutchings, MD, Michael Fuchs, Andreas Engert, MD, Carsten Kobe, MD, Peter Borchmann, MD

Blood (2018) 132 (Supplement 1): 926.

https://doi.org/10.1182/blood-2018-99-119363

Published: 2018

Journal Articles

Clinical and Biological Features behind Hallmark Aberrations in Diffuse Large B-Cell Lymphoma

Leo Meriranta, MS, Annika Pasanen, MD PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Sandeep Dave, MD, Sirpa Leppa, MD Prof

Blood (2018) 132 (Supplement 1): 2976.

https://doi.org/10.1182/blood-2018-99-117958

Published: 2018

Journal Articles

Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 1595.

https://doi.org/10.1182/blood-2018-99-114842

Published: 2018

Journal Articles

Outcomes for Patients with Pre-Existing Diabetes or Hypertension Treated with Copanlisib from the CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

Pier Luigi Zinzani, MD, Armando Santoro, MD, Luigina Mollica, MD FRCPC, PhD, Sirpa Leppä, MD PhD, George A Follows, MD PhD, Georg Lenz, Won Seog Kim, MD PhD, Arnon Nagler, MD, Panayiotis Panayiotidis, MD PhD, Judit Demeter, MD PhD Dr. Sci, Franck Morschhauser, MD, Liana Rodrigues, MD, John Reeves, PhD MS, Florian Hiemeyer, MSc, Ashok Miriyala, MD, Jose Garcia-Vargas, MD, Barrett H. Childs, MD, Martin H. Dreyling, MD PhD

Blood (2018) 132 (Supplement 1): 1613.

https://doi.org/10.1182/blood-2018-99-117063

Published: 2018

Journal Articles

Young High Risk Patients with MYC/BCL2 Double Hit Lymphoma, BCL2+ and/or Germinal Centre B-Cell like Diffuse Large B-Cell Lymphoma Benefit from Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis: Analysis of Data from the Nordic Lymphoma Group CRY-04 and Chic Trials

Sirpa Leppa, MD Prof, Judit Jørgensen, MD PhD, Leo Meriranta, MS, Klaus Beiske, MD PhD, Jan M.A. Delabie, MD PhD, Elisabeth Ralfkiaer, MD DMSC, Signe Spetalen, MD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Harald Holte, MD PhD

Blood (2018) 132 (Supplement 1): 2955.

https://doi.org/10.1182/blood-2018-99-120057

Published: 2018

Journal Articles

Characterization of Immunological Profiles with Clinical Significance in Patients with Classical Hodgkin Lymphoma

Kristiina Karihtala, Suvi-Katri Leivonen, PhD, Marja-Liisa Karjalainen-Lindsberg, Sirpa Leppa, MD

Blood (2017) 130 (Supplement 1): 4015.

https://doi.org/10.1182/blood.V130.Suppl_1.4015.4015

Published: 2017

Journal Articles

Low Expression of T/NK-Cell Signature Predicts Poor Survival in Patients with Primary Testicular and Diffuse Large B-Cell Lymphoma

Suvi-Katri Leivonen, PhD, Marjukka Pollari, MD, Oscar Brück, Teijo Pellinen, PhD, Marja-Liisa Karjalainen-Lindsberg, Susanna Mannisto, MD PhD, Pirkko-Liisa Kellokumpu-Lehtinen, MD prof, Satu Mustjoki, MDPhD, Sirpa Leppa, MD

Blood (2017) 130 (Supplement 1): 4027.

https://doi.org/10.1182/blood.V130.Suppl_1.4027.4027

Published: 2017

NARROW

Outcome of Nodular Lymphocyte Predominant Hodgkin Lymphoma: A Finnish Nationwide Population-Based Study

Clinical Impact of Tumor-Associated Macrophage and T-Cell Contents in Diffuse Large B-Cell Lymphoma

Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma

Mutational Dynamics and Evolutionary Divergence in DLBCL: A Call for Relapse Sampling

Genomic Profiling of Circulating Tumor DNA Reveals Patterns of Response and Refractoriness in Aggressive B-Cell Lymphoma - a Nordic Lymphoma Group Correlative Study

The DLBCL90 Double-Hit Gene Expression Signature Is Not Associated with Inferior Survival in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma Treated with Dose-Intensive Immunochemotherapy

Molecular Background of Double Protein Expressor B-Cell Lymphomas

Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies

Molecular Profiling of Aggressive Non-Hodgkin Lymphoma - Results from a Phase 1/2 Preben Study

Tumor Microenvironment Differs between Germinal Centre B-Cell and Non-Germinal Centre B-Cell like Diffuse Large B-Cell Lymphomas and Has Subtype-Specific Prognostic Impact on Survival

Immunogenomic Landscape of Hematological Malignancies

Outcomes for Patients with High-Risk Relapsed or Refractory Indolent B-Cell Lymphoma Treated with Copanlisib in the CHRONOS-1 Study

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)

Clinical and Biological Features behind Hallmark Aberrations in Diffuse Large B-Cell Lymphoma

Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

Outcomes for Patients with Pre-Existing Diabetes or Hypertension Treated with Copanlisib from the CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

Young High Risk Patients with MYC/BCL2 Double Hit Lymphoma, BCL2+ and/or Germinal Centre B-Cell like Diffuse Large B-Cell Lymphoma Benefit from Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis: Analysis of Data from the Nordic Lymphoma Group CRY-04 and Chic Trials

Characterization of Immunological Profiles with Clinical Significance in Patients with Classical Hodgkin Lymphoma

Low Expression of T/NK-Cell Signature Predicts Poor Survival in Patients with Primary Testicular and Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only